However, these findings suggest that the subtle variation noted in populations at the rs2159213 locus containing SF3A2 may more profoundly cause variation among individuals with an acquired blood disorder, such as MDS, illustrating the value of such a gene-centric study to identify potential disease modifiers. This evidence concerns the gene SF3A2 and myelodysplastic syndrome.